(Q34067972)

30 July 2017

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma (English)

1 reference

30 July 2017

Julie Teruya-Feldstein

2

object named as

Julie Teruya-Feldstein

0 references

William H. Westra

3

object named as

William H Westra

1 reference

30 July 2017

Justin A Bishop

1

1 reference

30 July 2017

Giuseppe Pelosi

4

1 reference

30 July 2017

William D Travis

5

1 reference

30 July 2017

Natasha Rekhtman

6

1 reference

30 July 2017

4 November 2011

1 reference

30 July 2017

1 reference

30 July 2017

25

1 reference

30 July 2017

405-415

1 reference

30 July 2017

3

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.173

30 July 2017

0 references

cites work

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Cytology applications of p63 and TTF-1 immunostaining in differential diagnosis of lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

P63 expression in lung carcinoma: a tissue microarray study of 408 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

miR-205 Expression levels in nonsmall cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Accurate classification of non-small cell lung carcinoma using a novel microRNA-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, S100A2, S100A7, and Sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the Lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Frequent ALK rearrangement and TTF-1/p63 co-expression in lung adenocarcinoma with signet-ring cell component.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Constitutive expression of DeltaN-p63alpha isoform in human thymus and thymic epithelial tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Expression of p63 in anaplastic large cell lymphoma but not in classical Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Expression of p63 in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Expression of p63 in reactive hyperplasias and malignant lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Differential expression of p63 isoforms in normal tissues and neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

p63 in epithelial survival, germ cell surveillance, and neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

p63 Is essential for the proliferative potential of stem cells in stratified epithelia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Dominant negative p63 isoform expression in head and neck squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

AIS is an oncogene amplified in squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

The role of p63 and ΔNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Expression of TP73L is a helpful diagnostic marker of primary mediastinal large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

The transactivating isoforms of p63 are overexpressed in high-grade follicular lymphomas independent of the occurrence of p63 gene amplification.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Desmocollin-3: a new marker of squamous differentiation in undifferentiated large-cell carcinoma of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

The diagnostic value of TTF-1, CK 5/6, and p63 immunostaining in classification of lung carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

TTF-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

p63 protein expression in high risk diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

Clinico-pathological characteristics of p63 expression in B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

Pleomorphic large cell lymphomas of the mediastinum

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

Primary anaplastic large cell lymphoma of the lung: a clinicopathologic study of five patients

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

Abnormal re-epithelialization and lung remodeling in idiopathic pulmonary fibrosis: the role of deltaN-p63.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

Immunohistochemical detection of XIAP and p63 in adenomatous hyperplasia, atypical adenomatous hyperplasia, bronchioloalveolar carcinoma and well-differentiated adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.173

7 January 2021

10.1038/MODPATHOL.2011.173

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference